PFE - Pfizer Inc.

There's no reason for investors to sell stocks now: NYSE trader

Alan Valdes, director of floor operations at Silverbear Capital, joins Yahoo Finance's Alexis Christoforous from the floor of the New York Stock Exchange to discuss current headwinds for US equities, including the nomination of a new (or same) Federal Reserve Chair in a few weeks.

• 
  Buyers never came in that Monday in '87—it was chaos: NYSE trader

  Yahoo Finance Video
• 
  I'm bullish on American Express and Verizon: NYSE trader

  Yahoo Finance Video

Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?

The performance of GlaxoSmithKline plc's (GSK) new products is likely to be good. Vaccines acquired from Novartis are likely to drive revenues and ease the impact of the loss of key drug, Advair .

3 High-Yield Pharmaceutical Stocks

High-yield pharma stocks are rare, but these three offer comparatively fat payouts.

See what the IHS Markit Score report has to say about Pfizer Inc.

Pfizer Inc NYSE:PFE

Healthcare ETFs Head to Head: XLV vs. VHT

Head to head comparison of two Healthcare ETFs, XLV and VHT.

3 Reasons to Stay Away From Valeant Pharmaceuticals Intl Inc Stock

During the past six months or so, Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has been regaining some of its footing. CEO Joe Papa has wasted little time in cutting costs, streamlining the business and unloading of VRX stock’s assets. Since April, VRX stock has rallied from $8.60 to $12.81.

Conatus Entrusts Keith W. Marshall With Key Management Roles

Conatus Pharmaceuticals (CNAT) announced the appointment of Keith W. Marshall as executive vice president, chief operating officer and chief financial officer.

2 Great Stocks For Retirees

Find out what makes this pair of big pharma stocks a perfect fit for recent retirees looking to bolster their income.

3 High-Yield Stocks for Conservative Investors

These solid businesses with great dividend yields hit the sweet spot for conservative investors.

What to Expect from Big Pharmas After J&J's Solid Q3 Results?

Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.

Here's Why Ignyta Stock Soared as Much as 27.5% Today

The biopharma's lead drug candidate has strong potential based on a sneak peek at midstage trial data.

Dow Jones Industrial Average Hits 23,000. Now What?

On Oct. 18, the Dow Jones Industrial Average hit a new all-time intraday high of 23,145 as of this writing. Investors who aren’t playing the indices can gain exposure to the Dow Jones today through the SPDR Dow Jones Industrial Average ETF (NYSEARCA:DIA). With the index up 16.3% in 2017, though, how much longer can this rally continue?

Reckitt to reshape as sales growth evaporates

Britain's Reckitt Benckiser will split its business into two divisions -- consumer healthcare and home and hygiene products -- to try to revive sales that are set to stall this year. It hopes to improve performance in its newly expanded health business, while bringing greater focus and accountability to its slower-growth home and hygiene business. Reckitt, whose products range from Durex condoms to Lysol disinfectant, has blamed fallout from a cyber attack, a failed product launch and a safety scandal in South Korea for its lacklustre sales.

Pfizer's Advil May Be Just the Thing for Sickly Reckitt

The problem is getting shareholders to back a cash call to pay for it.

Reckitt CEO Focuses on Health, Looking Beyond Worst Year

Reckitt Benckiser Group Plc separated its home-care and health businesses, sharpening its focus on brands such as Durex condoms and Enfamil baby formula after a second cut in the sales forecast this year....